Torrent Pharmaceuticals
TORNTPHARM
Torrent Pharmaceuticals Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 1,98,336 |
| Weekly | 6.39% | 20,49,082 |
| Monthly | 12.63% | 41,98,950 |
Torrent Pharmaceuticals Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| TORNTPHARM | - | 6.39% | 12.63% |
| Index | - | - | - |
| Peer Avg. | 0.03% | 5.45% | 11.54% |
Torrent Pharmaceuticals Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| TORNTPHARM | 27.16 | 7.70 | 21.28 | 14.60 | 15.65 | 3.09 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Torrent Pharmaceuticals Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 5.41% | -25.39% | 14.60% | 15.65% |
| FY '20-21 | 2.70% | 21.70% | 21.95% | 16.96% |
| FY '19-20 | 5.26% | 80.38% | 19.99% | 14.98% |
Torrent Pharmaceuticals Shareholding Pattern
Torrent Pharmaceuticals Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 7,625.18 | 5,359.17 | 2,466.38 | 884.32 |
| FY '20-21 | 7,227.57 | 4,891.66 | 2,423.53 | 1,194.87 |
| FY '19-20 | 7,053.88 | 5,010.20 | 2,222.79 | 981.62 |
Torrent Pharmaceuticals Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| TORNTPHARM | 7,625.18 | 5,359.17 | 2,466.38 | 884.32 |
| ZYDUSLIFE | 11,623.55 | 9,000.35 | 2,831.10 | 1,592.15 |
| CIPLA | 17,427.56 | 13,488.35 | 4,433.43 | 2,624.43 |
Torrent Pharmaceuticals Share Price
Torrent Pharmaceuticals Limited is an Indian pharmaceutical company. The company's field of activity is the research, development, production and marketing of generic medicines. It operates in the therapeutic segments Cardiovascular (CV), Gastrointestinal (GI), Central and Central Nervous System, and Vitamin, Mineral Nutrients (VMN). It is also used in therapeutic areas such as anti-epileptic drugs, diabetes treatment, anti-cancer drugs, anti-acne drugs, corticosteroids and cosmetics. It is complex dosage forms developed for the global market based on oral solids, injections, inhalation technologies, long-term depot injections for ophthalmic, nasal, semi-solids for external use and multiparticulate sustained-release oral systems. The company develops various in-house new chemical entities (NCE) in the areas of metabolic, cardiovascular, gastrointestinal, dermatology and respiratory diseases. It is represented in more than 40 countries.